A Study to Compare PK, PD and Safety of the AD-214 and AD-2141

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 1, 2021

Primary Completion Date

March 17, 2022

Study Completion Date

March 29, 2022

Conditions

Gastroesophageal Reflux Disease

Interventions

DRUG

AD-214

1 tablet administered before the breakfast during 7 days

DRUG

AD-2141

1 tablet administered before the breakfast during 7 days

Trial Locations (1)

Seoul National University Hospital, Seoul

All Listed Sponsors

lead

Addpharma Inc.

INDUSTRY

NCT05062876 - A Study to Compare PK, PD and Safety of the AD-214 and AD-2141 | Biotech Hunter | Biotech Hunter